bHighlights:/b
ul class="group-list"
li Perioperative durvalumab, combined with platinum-based chemotherapy, significantly improved event-free survival and pathologic complete response rates for patients with operable non-small cell lung cancer /li
li Durvalumab is an immune checkpoint inhibitor that targets PD-L1, and this study suggests it has the potential to increase the percentage of lung cancer cures significantly /li
li The study showed that the combination of neoadjuvant ...
bHighlights:/b
ul class="group-list"
li Perioperative durvalumab, combined with platinum-based chemotherapy, significantly improved event-free survival and pathologic complete response rates for patients with operable non-small cell lung cancer /li
li Durvalumab is an immune checkpoint inhibitor that targets PD-L1, and this study suggests it has the potential to increase the percentage of lung cancer cures significantly /li
li The study showed that the combination of neoadjuvant ...